Webinars » Design and Development of Innovative Bi-Specific Antibodies

Design and Development of Innovative Bi-Specific Antibodies

In this webinar we introduce therapeutic antibodies, focusing on the opportunities and challenges of current monotherapy. We analyze the major benefits of bispecific antibodies and the current formats used in clinical trails. Additionally, we share an in-depth, integrated SMAB (single-domain antibody fused to monoclonal antibody) case study from rational design to preclinical development.

    manzhu phd
  • Speaker: Dr. Li Chen, Associate Director of Discovery, GenScript ProBio
  • Date: Feb.2nd, 2021
  • Time: 12:30-13:00PM UTC

Speaker Profile

Li Chen, Ph.D, Senior Project Manager, GenScript ProBio. Dr. Chen received his Ph.D. from the University of Massachusetts Medical School, specializing in antigen Engeneering, Dr. Chen has extensive experience in Antibody drug discovery, he has published over 8 highly-cited papers in immunology, virology, and biochemistry Journals, and has received few patents in the antibody discovery field.

BS of Bioinformatics from Zhejiang University of China; PhD training of immunology from University of Massachusetts Medical School. After joining GenScript, Dr. Chen is in charge of the antibody drug discovery services, and has more than 10 years’ experience in immunology, antibody drug discovery and engineering, managing over 300 antibody drug discovery/engineering projects.

Related Services

Innovative SMABody Bispecific Antibody Discovery Services

GenScript ProBio SMABody(Single-domain antibody fused to monoclonal Ab) platform naturally combine the single domain antibody and the monoclonal antibody to make a bispecific antibody in symmetric format with good biological efficacy and good developability.

Anti-idiotype antibody generation and applications in antibody drug discovery
Anti-idiotypic Antibody Service DNA Immunization Service Therapeutic Hybridoma Development
  • High specificity & affinity
  • Fast turnaround time: 2-3 months.
  • 100% success rate
  • Solution to problematic antigens, such as membrane proteins
  • Proven track record with 100% success rate
  • Full spectrum of immunization approaches
  • One stop solution
  • High throughput screening